MedTrace Logo

Oxytocin Add-on for Stable Depressed Patients

NCT01211756 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-09-25

Study results available
· View outcomes & findings →

Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve depression symptoms in patients with Major Depressive Disorder (MDD) or Dysthymia Disorder.

Conditions

Interventions

DRUG

Oxytocin

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

DRUG

Placebo

20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Sponsors & Collaborators

  • David Feifel

    lead OTHER

Principal Investigators

  • David Feifel, MD, PhD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-02-28
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01211756 on ClinicalTrials.gov